34.99

6.55% 2.15

Oruka Therapeutics Inc (ORKA)

Overview News Price History Discussions Forecast

Oruka Therapeutics Inc stock is traded at $34.99, with a volume of 500.05K. It is up +6.55% in the last 24 hours and up +6.03% over the past month. Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Previous Close:

$32.84

Open:

$33.34

24h Volume:

500.05K

Relative Volume:

1.01

Market Cap:

$1.69B

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-0.82%

1M Performance:

+6.03%

6M Performance:

+133.73%

1Y Performance:

+245.07%

1-Day Range:

$32.24

$35.66

1-Week Range:

$31.86

$35.66

52-Week Range:

$5.485

$36.53

Oruka Therapeutics Inc Stock (ORKA) Company Profile

Name

Oruka Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (621)

Phone

650-606-7910

Address

855 OAK GROVE AVE., MENLO PARK

Employee

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

ORKA's Discussions on Twitter

Compare ORKA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ORKA Oruka Therapeutics Inc	34.99	1.59B	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-18-25	Initiated	Piper Sandler	Overweight
Nov-13-25	Initiated	Jefferies	Buy
Oct-27-25	Initiated	Guggenheim	Buy
Oct-13-25	Initiated	Barclays	Overweight
May-22-25	Initiated	BTIG Research	Buy
Feb-04-25	Initiated	Wolfe Research	Outperform
Oct-11-24	Initiated	Stifel	Buy
Oct-07-24	Initiated	H.C. Wainwright	Buy
Sep-17-24	Initiated	Leerink Partners	Outperform
Sep-16-24	Initiated	TD Cowen	Buy
Sep-13-24	Initiated	Jefferies	Buy
Feb-27-18	Initiated	Ascendiant Capital Markets	Buy
Oct-09-13	Initiated	Dawson James	Buy

View All

Oruka Therapeutics Inc Stock (ORKA) Latest News

Mar 03, 2026

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Down 17.2% in February - MarketBeat

Mar 03, 2026

Is Oruka Therapeutics Inc. forming bullish engulfing patternsJuly 2025 Rallies & Smart Allocation Stock Reports - mfd.ru

Mar 03, 2026

Mar 02, 2026

Oruka Therapeutics Inc expected to post a loss of 63 cents a shareEarnings Preview - TradingView

Mar 02, 2026

Feb 28, 2026

Oruka Therapeutics (NASDAQ:ORKA) Upgraded at Wall Street Zen - Defense World

Feb 28, 2026

Feb 27, 2026